BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia

Abstract

Background BCL2 protein inhibitor venetoclax (ABT-199) has been authorized by Food and Drug Administration for relapsed/refractory chronic lymphoid leukemia with 17p deletion. Although venetoclax/ABT-199 also caused cell death in acute myeloid leukemia (AML), whether it could be applied to clinical treatment needs further studies. Here, we revealed clinical implication of BCL2 overexpression in de novo adult AML, and may provide theoretical basis for targeted therapy using venetoclax. Methods BCL2 expression was analyzed in adult AML patients from public datasets The Cancer Genome Atlas (TCGA) and confirmed by another independent cohort from our own data. Results BCL2 expression showed up-regulated in AML patients among TCGA data and confirmed by our own data. BCL2 overexpression was correlated with FAB-M0/M1, whereas BCL2 under-expression was related to FAB-M5. However, BCL2 expression has no effect on overall survival (OS) and leukemia-free survival (LFS) of AML patients (determined in BCL2 low and BCL2 high groups). Interestingly, in the BCL2 low group, patients undergoing autologous or allogeneic hematopoietic stem cell transplantation (auto/allo-HSCT) had significantly better OS and LFS compared with patients only received chemotherapy, whereas, no significant difference was found in OS and LFS between chemotherapy and auto/allo-HSCT patients in the BCL2 high group. BCL2 expression was found positively correlated with HOX family gene, and negatively correlated with tumor suppressor microRNA such as miR-195 , miR-497 , and miR-193b . Conclusions BCL2 overexpression identified specific FAB subtypes of AML, but it did not affect prognosis. Patients with BCL2 overexpression did not benefit from auto/allo-HSCT among whole-cohort-AML and cytogenetically normal AML. Electronic supplementary material The online version of this article (10.1186/s13000-019-0841-1) contains supplementary material, which is available to authorized users.

The role of ARHGAP9: clinical implication and potential function in acute myeloid leukemia

“…Despite the association of the high expression of ARHGAP9 with CN-AML, no relationship between ARHGAP9 expression and prognosis of CN-AML was found in the current study. In addition, several studies have shown that abnormal expression of some genes such as NCALD, IL2RA , and BCL2 are associated with prognosis in AML patients with auto/allo-HSCT and/or chemotherapy [ 41 – 43 ]. Our findings showed that ARHGAP9 high groups had poor prognosis in post-chemotherapy AML patients, whereas no significant differences in OS and EFS were found between the ARHGAP9 high group and ARHGAP9 low group in patients who underwent after auto/allo-HSCT.…”

Identification and validation of obesity-related gene LEP methylation as a prognostic indicator in patients with acute myeloid leukemia

“…Differential expression analysis for RNA/miRNA sequencing data was calculated using the raw read counts with the R/Bioconductor package “edgeR”, all analyses were controlled for the false discovery rate (FDR) by the Benjamini–Hochberg procedure [ 24 ]. The miRNA which could target LEP was identified by the venn analysis ( http://bioinformatics.psb.ugent.be/webtools/Venn/ ) of three websites miRDB ( http://mirdb.org/miRDB/ ), miRWalk ( http://mirwalk.umm.uni-heidelberg.de/ ) and TargetScan ( http://www.targetscan.org/vert_72/ ) [ 25 , 26 ]. All basic statistical analyses were performed using the base functions in R version 3.4 ( https://www.r-project.org ).…”

Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence

“…Bcl-2 is often overexpressed in AML patients, both at diagnosis as well as at relapse and can render resistance to cytotoxic chemotherapeutics [271,272]. A major finding by Lagadinou et al identified high levels of Bcl-2 as a feature of LSCs to maintain mitochondrial integrity for survival [27].…”